The majority of CD8+ TILs did not express CD25 or CD137 (<5% and <14% of total CD8+ TILs, respectively), with CD25+ and CD137+ CD8+ TIL frequencies remaining stable throughout tumour outgrowth (Figures 5F, G). This evidence concerns the gene TNFRSF9 and neoplasm.